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Abstract
Background: Chicken anemia virus (CAV), the causative agent chicken anemia, is the only member of the genus
Gyrovirus of the Circoviridae family. CAV is an immune suppressive virus and causes anemia, lymph organ atrophy
and immunodeficiency. The production and biochemical characterization of VP1 protein and its use in a subunit
vaccine or as part of a diagnostic kit would be useful to CAV infection prevention.
Results: Significantly increased expression of the recombinant full-length VP1 capsid protein from chicken anemia
virus was demonstrated using an E. coli expression system. The VP1 gene was cloned into various different
expression vectors and then these were expressed in a number of different E. coli strains. The expression of CAV
VP1 in E. coli was significantly increased when VP1 was fused with GST protein rather than a His-tag. By optimizing
the various rare amino acid codons within the N-terminus of the VP1 protein, the expression level of the VP1
protein in E. coli BL21(DE3)-pLysS was further increased significantly. The highest protein expression level obtained
was 17.5 g/L per liter of bacterial culture after induction with 0.1 mM IPTG for 2 h. After purification by GST affinity
chromatography, the purified full-length VP1 protein produced in this way was demonstrated to have good
antigenicity and was able to be recognized by CAV-positive chicken serum in an ELISA assay.
Conclusions: Purified recombinant VP1 protein with the gene’s codons optimized in the N-terminal region has
potential as chimeric protein that, when expressed in E. coli, may be useful in the future for the development of
subunit vaccines and diagnostic tests.
Background
Chicken anemia virus (CAV), is the causative agent of
chicken anemia disease. The disease results in severe
anemia, lymph organ atrophy and immunosuppression
[1-3]. CAV is the sole member of the genus Gyrovirus
of the Circoviridae family. Histopathological studies
have also shown that CAV infection leads to aplasia of
the bone marrow and the destruction of T lymphoid tis-
sue in young chickens [4,5]. When chicks are infected
with CAV, the mortality rate is often as high as 55%
and morbidity rates of 80% have been reported [6].
Therefore, worldwide, CAV is an economically impor-
tant veterinary virus that can seriously affect the poultry
industry.
VP1 protein (51 kDa) is the sole structural protein
found within the CAV capsid. At a very late stage of the
virus life cycle, the assembled virus particles created by
VP1 protein spread into various other tissues and organs
in the chicken, such as the thymus, spleen and liver [4].
Immunogenicity studies have shown that VP1 allows the
elicitation of host-produced virus neutralizing antibodies
[7]. Thus, VP1 is thought to be a good candidate for use
as an immunogen when developing subunit vaccines
and diagnostic kits [7,8]. Up to the present, a number of
different expression systems have been used to produce
VP1 protein, including E. coli, baculovirus-insect cells
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recombinant full-length VP1 protein has generally been
unsuccessful because of a failure to express a span of
amino acids at the N-terminus of the VP1 protein that
is highly rich in arginine residues [9,11]. Furthermore,
VP1 has been proposed to be cytotoxic in an E. coli
expression system [9]. Once the N-terminus of VP1 is
deleted, protein expression is improved significantly
[11]. Nevertheless, the N-terminus of VP1 may still be
involved in eliciting neutralizing antibodies because it
contains some functional epitopes. Thus, there is a need
to overcome the difficulties that have been encountered
during production of full-length VP1 protein using an E.
coli expression system. If successful, it would not only
allow the efficient development of a subunit vaccine that
is active against chicken anemia virus infection but the
recombinant protein will also be potentially useful when
developing diagnostic kits for the clinical detection of
CAV infection.
As can be seen from the above information, E. coli has
a number of disadvantages and limitations when produ-
cing CAV VP1 protein. However, the expression of VP1
protein in E. coli is still an attractive alternative to the
current production system when assessed with respect
to cost, time and operational considerations. In this
study, we investigated the effect on expression of VP1 of
changes in codon usage for various amino acids within
the N-terminus of VP1 gene; this is because these
amino acids are encoded by codons that are rarely used
by E. coli. The codons within the N-terminus of the
VP1 protein were optimized using prediction software
and changed to the preferred codon usage for E. coli.I n
addition, VP1 was cloned into the expression vector,
pGEX-4T-1, in order to create a glutathione-S-transfer-
ase (GST) fusion protein with the N-terminus of VP1.
Expression of the modified VP1 genes was examined in
various E. coli strains and changes in CAV VP1 protein
expression determined. To the best of our knowledge,
the yield of E. coli expressed recombinant VP1 in this
study, after codon optimization of the N-terminal
region, is the highest known to date.
Results
GST fusion tag enhances the expression of recombinant
CAV VP1 protein in E. coli
To investigate the effect of fusion tags on the expression
of full-length VP1 protein of CAV in E. coli expression
systems, the cDNA of VP1 was cloned into the pET-28a
and pGEX-4T-1 vectors to obtain His tagged and GST
tagged proteins. These constructs were designated to be
pET28a-VP1 and pGEX-4T-1-VP1, respectively, and
shown in Figure 1A. Using these two constructs, the
expression of full-length VP1 protein in E. coli BL21
(DE3) was examined. As shown in Figure 2, the full-
length VP1 protein obtained from whole cell lysate was
only expressed to any obvious extent in the recombinant
E. coli harboring pGEX-4T-1-VP1 after IPTG induction
for 4 h (Figure 2B, SDS-PAGE and Western-blot). The
approximately 78 kDa GST-VP1 protein was recognized
by monoclonal anti-GST antibody (Figure 2B, lane 4 of
Western-blot). The induced control cell lysate contain-
ing pGEX-4T-1-VP1 plasmid without IPTG induction
w a sn o ts h o w e dt h ep r e s e n c eo fa ne x t r ab a n da t7 8
k D a( F i g u r e2 B ,l a n e1o fS D S - P A G E ,l a n e3o fW e s -
tern-blot). In contrast, VP1 was almost undetectable by
Western-blot assay when anti-His tag antibodies (Figure
2A, lane 2 of SDS-PAGE and lane 4 of Western-blot)
were used on the cell lysate from IPTG induced
Figure 1 Schematic diagram of the constructs used for CVA
VP1 protein expression. (A) Schematic representation of the VP1
protein variants and expression vectors used in this study. The
designations of the VP1 protein and its expression vectors are
indicated, a, b and c. The first two constructs, a and b, contained
the full-length VP1 gene cloned into vectors pET28a and pGEX-4T-1,
for expression of VP1 protein with a six-histidine (6 × His) tag and
glutathione-s-transferase (GST) tag at its N-terminus, respectively.
Construct c contained VP1 gene with codon-optimized at its N-
terminus; this was derived from construct b by replacing the rare
codons in the area 1-321 bp without altering amino acid sequence.
The N-terminal codon-optimized VP1 gene, opt-N, was fused with
C-terminal domain of VP1 gene (VP1 C-term) by overlapping PCR,
and then cloned into pGEX-4T-1. (B) Sequence comparison between
the WT VP1 and Opt VP1 gene. The nucleotide sequences were
compared between the original VP1 gene (WT VP1) and the
sequence of codon-optimized VP1 gene (Opt VP1) over the N-
terminal region. An asterisk (*) represents the fact that the aligned
nucleotides are identical.
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Page 2 of 11recombinant E. coli harboring pET28a-VP1. These
results illustrated that the GST fusion tag improved pro-
tein expression significantly and allowed detectable
amounts of intact full-length CAV VP1 protein to be
produced in E. coli.
Growth profile and expression levels of recombinant GST-
VP1 protein in various different E. coli strains
To further address the expression level of GST-VP1
protein in E. coli, three E. coli strains, BL21(DE3), BL21-
CodonPlus(DE3)-RP and BL21(DE3)-pLysS were trans-
formed with pGEX-4T-1-VP1 and used for protein
induction and expression. Figures 3A and 3B demon-
strate the protein expression pattern for identical
amounts of whole cell lysate across the three E. coli
strains, analyzed by SDS-PAGE and Western blotting.
All three E. coli s t r a i n sw e r ea b l et oe x p r e s sb a n d sa t
the expected molecular mass of GST-VP1 protein after
IPTG induction for 4 h (Figure 3A). Densitometric ana-
lysis of the blots showed that total expressed GST-VP1
protein, both soluble and insoluble, from BL21(DE3)-
pLysS was one to two folds greater than the amounts
produced by BL21-CodonPlus(DE3)-RP and BL21(DE3)
(Figure 3B). The quantitative yields of GST-VP1 protein
from BL21(DE3), BL21(DE3)-pLysS and BL21-Codon-
Plus(DE3)-RP, were induced for 1-4 h, and presented in
Figure 4B, C and 4D, respectively. The amount of GST-
VP1 protein produced by the three different strains was
almost identical at 1 h of IPTG induction at 1.14 mg/ml
for BL21(DE3), 1.08 mg/ml for BL21(DE3)-pLysS and
1.71 mg/ml for BL21-CodonPlus(DE3)-RP. After 2 h of
induction, the expression level of GST-VP1 in BL21
(DE3) and BL21(DE3)-pLysS both rose steadily, but had
slowed down in BL21-CodonPlus(DE3)-RP (Figure 4B, C
and 4D). The expression of GST-VP1 in BL21(DE3)-
pLysS continued to increase significantly in BL21(DE3)
over 2-4 h induction range but remained steady for
BL21-CodonPlus(DE3)-RP (Figure 4B, C and 4D). These
strains also show significant differences in their growth
profiles. The optical density with 600 nm wave length
(OD600) value reached by BL21-CodonPlus(DE3)-RP is
higher than those of BL21(DE3)-pLysS and BL21(DE3)
Figure 2 VP1 protein expression in E. coli using various
expression vectors. The VP1 protein expression in E. coli BL21(DE3)
using the expression vectors, pET28a (A) and pGEX-4T-1 (B) was
analyzed by SDS-PAGE and Western-blotting. Anti-His tag and anti-
GST tag monoclonal antibody were respectively used for the
recognition of differently tagged VP1 proteins expressed by the
different expression vectors used. Lane M, pre-stained protein
marker; lane 1 and lane 3, before IPTG induction; lane 2 and 4, after
IPTG induction for 4 h cultivation. The solid triangle pinpoints the
expressed VP1 protein.
Figure 3 Expression of recombinant GST-VP1 protein in three
different E. coli strains. The GST-VP1 protein expression in three E.
coli strains, BL21(DE3), BL21-CodonPlus(DE3)-RP and BL21(DE3)-pLysS
all containing pGEX-4T-1-VP1 was examined. The GST-VP1 protein
was examined and detected using SDS-PAGE (A) and Western-
blotting (B). Anti-GST tag monoclonal antibody was used to
recognize the VP1 protein. Lane M, pre-stained protein marker; lane
1, 4 and 7, before IPTG induction; lane 2, 5 and 8, after IPTG
induction for 1 hrs cultivation; lane 3, 6 and 9, after IPTG induction
for 4 h cultivation. The solid triangle pinpoints the expressed VP1
protein.
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is less (Figure 4A). Therefore, it can be concluded that
BL21(DE3)-pLysS is the optimal host strain for produ-
cing full-length VP1 protein.
Optimization of codon usage enhances the expression of
recombinant CAV VP1 protein in E. coli
Based on the results shown in Figure 2B, we concluded
that the expression of the full-length VP1 protein in E. coli
was improved by fusing a GST tag to the N-terminus of
VP1 protein. However, the expression of full-length VP1
protein in E. coli still gave a relatively low yield of GST-
VP1 even when the optimal host strain BL21(DE3)-pLysS
was used (Figure 4B). To further enhance the expression
level of VP1, the codon usage of the VP1 gene was
explored and optimized. To this end the CAV wild type
VP1 gene was analyzed by PSORT II prediction http://
psort.ims.u-tokyo.ac.jp/. The first 107 amino acid residues
at the N-terminus of VP1 were found to contain many
basic amino acid residues such as arginine and lysine
(Figure 1B). The codons for these amino acids within the
N-terminus of VP1 were then explored using the Gen-
Script rare codon analysis tool http://www.genscript.com/
index.html (Figure 1B). Clusters of rare codons are present
in the 5’ end of VP1 gene and therefore the CAV VP1
gene was optimized from base pairs 1-321 to E. coli’s pre-
ferred codons as selected by GeneOptimizer software.
This was done without altering the amino acid sequence
to be over-expressed in E. coil, which is confirmed by Fig-
ure 1B. The 321 bp DNA fragment from the N-terminus
of VP1 protein was engineered to have the rare codons
replaced by E. coli’s favored codons (AGA/CGA/CGG to
CGT (R), CCC to CCG (P), CTC/CTT/CTT to CTG (L),
GGA/GGG to GGT (G), ACT/ACA to ACC (T), CAA to
CAG (Q) and ATA to ATC (I)) (Figure 1B). The new
codon usage produced a better balance with respect to E.
coli as indicated by the GeneOptimizer software. The new
N-terminal codon optimized VP1 gene regions was
assembled with the C-terminus of the VP1 gene to give an
intact open reading frame using an overlapping PCR
Figure 4 Growth kinetics and production profiles of GST-VP1 protein in three E. coli strains.( A )G r o w t hp r o f i l eo fB L 2 1 ( D E 3 ) ,B L 2 1 -
CodonPlus(DE3)-RP and BL21(DE3)-pLysS in LB medium post-induction. The production profiles of the three E. coli strains, (B)BL21(DE3)-pLysS, (C)
BL21(DE3) and (D)BL21-CodonPlus(DE3)-RP containing pGEX-4T-1-VP1 are shown over time course after IPTG induction.
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opt-VP1 was then cloned into pGEX-4T-1 to give pGEX-
4T-1-optVP1. This was then used for protein expression.
As shown in Figure 5, the protein expression pattern of
whole cell lysate in the E. coli strains BL21(DE3)-pLysS
and BL21(DE3) were analyzed by SDS-PAGE and Western
blotting. It was found that GST-opt-VP1 protein was suc-
cessfully expressed after IPTG induction. The GST-opt-
VP1 protein migrated at a expect molecular weight of 78
kDa in both BL21(DE3)-pLysS and BL21(DE3) and protein
identity was confirmed by Western blotting using a mono-
clonal anti-GST antibody (Figure 5A and 5B, right panel).
The quantitative yields for the GST-opt-VP1 protein in
BL21(DE3)-pLysS reached to 17.5 mg/ml on the same
optical density (OD) of cultures represents a 4.6 fold
increase over wild type GST-VP1 expression (3.87 mg/ml)
(Figure 6B and 4B). The expression of GST-opt-VP1 pro-
tein in BL21(DE3)-pLysS was 6 fold higher than the GST-
opt-VP1 protein expression in BL21(DE3) (2.60 mg/ml),
both after 4 h IPTG induction. No significant difference in
the growth profiles of the two strains was observed post-
induction (Figure 6A). Thus, in addition to improving the
yield of full-length CAV VP1 protein using GST fusion,
we have also further improved expression by codon prefer-
ence optimization without altering the amino acid
sequence.
Purification of recombinant GST-opt-VP1 protein using
GST affinity chromatography
To purify GST-opt-VP1, the solubility of the expressed
GST-opt-VP1 was examined. The supernatant and
pellet obtained from a sonicated cell suspension was
used. SDS-PAGE showed that approximately 80% of
the GST-VP1 was soluble and this confirmed by Wes-
tern blot using monoclonal anti-GST antibody (Figure
7A, B). Purification of the E. coli-expressed GST-opt-
VP1 protein then proceeded using a GST affinity col-
umn. After affinity chromatography purification, the
eluted soluble GST-opt-VP1 protein was monitored
spectrophotometrically at OD280 and then separated by
SDS-PAGE. A typical elution profile of the protein
fraction collected from a GST column is shown in Fig-
ure 8A. Fraction 2 contains the most eluted protein
from the GST column, has a significant absorbent
peak at OD280 and was eluted at 12 min. The specific
78 kDa band eluted in fraction 2 was almost purified
to homogenicity (Figure 8B, lane 4). The purified GST-
opt-VP1 protein was then examined by MALDI-TOF
(Figure 8C). Eight peptides from GST-opt-VP1 protein
were identified after trypsin digestion and these
demonstrated good alignment and a high score with
the predicted protein. The longest peptide fragment of
VP1, FGTATYALKEPVMLSDAWAVVRVQSVWQLG
NR, consists of 32 amino acid residues (Figure 8C) and
overall the fragments covered 34% of the published
amino acid sequence of VP1 (Accession No. P54088)
was obtained without any miss-match. These MALDI-
TOF results confirmed that the purified 78 kDa pro-
tein was GST-opt-VP1 and that the E. coli preferred
codon usage optimization within the VP1 gene was not
seem to have altered the amino acid sequence of VP1
(Figure 8C; Figure 8B, lane 4)
Figure 5 GST-opt-VP1 protein expression in E. coli BL21(DE3)-pLysS (A) and BL21(DE3) (B). GST-opt-VP1 protein expression in E. coli BL21
(DE3) and BL21(DE3)-pLysS was demonstrated and analyzed by SDS-PAGE and Western-blotting. Anti-GST tag monoclonal antibody was used to
recognize VP1 protein when different expression vectors were used. Lane M, pre-stained protein marker; lane 1 and 4, before IPTG induction;
lane 2 and 5, after IPTG induction for 1 h cultivation; lane 3 and 6, after IPTG induction for 4 h cultivation. The solid triangle pinpoints the
expressed VP1 protein.
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Page 5 of 11Application of recombinant CAV VP1 protein to an
indirect ELISA
The recombinant full-length VP1 is a potent antigen
that could be used to develop a diagnostic kit. In this
context, the antigenicity of the recombinant GST-opt-
VP1 protein was explored. The GST column-purified
GST-opt-VP1 protein was found to exhibit good antige-
nicity when CAV-positive serum was used to recognize
the antigen (Figure 9A, lane 3). The protein identity of
GST-opt-VP1 was also examined by Western blotting
using a monoclonal anti-GST antibody and monoclonal
anti-VP1 E3 antibodies (Figure 9A, lane 1 and 2). The
results indicated that E. coli-expressed GST-opt-VP1
protein retains considerable antigenicity and can be
recognized by anti-CAV antibodies. In addition, to eval-
uate the possibility of developing a diagnostic kit, the E.
coli-expressed GST-opt-VP1 protein was used as a coat-
ing antigen to set up a GST-opt-VP1 based indirect
ELISA. As illustrated in Figure 9B, two hundred folds
diluted CAV-negative and CAV-positive specific chicken
sera were obtained from an experimental farm and used
to represent different antigenicity responses against the
GST-opt-VP1 protein using an ELISA approach; the
results were measured at OD405. Purified GST-opt-VP1
protein showed higher antigenicity with the CAV-posi-
tive specific chicken sera (Sera No. 1-5) than with the
CAV-negative chicken sera and there was a significant
difference between the OD405 values for the CAV-posi-
tive and CAV-negative sera (p < 0.01). Next a cut-off
value of 0.3 (Mean ± 2 fold standard deviation) was
determined using the CAV-negative sera and this was
used to define a positive threshold. Based on this criter-
ion, the OD405 values of all CAV-positive sera were
higher than this cut-off value. This indicates that CAV
positive/negative sera can be successfully discriminated
using the recombinant protein and this threshold. Thus,
the purified GST-opt-VP1 protein shows considerable
antigenic potential and able to pinpoint sera from chick-
ens that are infected with CAV and separate these from
the sera of uninfected chickens.
Discussion
In this study, the specific aim was to establish a prokaryo-
tic expression system for the production of full-length
recombinant CAV VP1 protein. A prokaryotic expression
Figure 6 Growth kinetics and production profiles of GST-opt-VP1 protein in E. coli BL21(DE3)-pLysS and BL21(DE3). (A) Growth profile
of BL21(DE3) and BL21(DE3)-pLysS in LB medium during post-induction. (B) The production profiles of the E. coli strains, (B)BL21(DE3)-pLysS, and
BL21(DE3) containing pGEX-4T-1-Opt-VP1 are shown after induction.
Figure 7 Distribution of E. coli-expressed GST-opt-VP1 protein
in the soluble and insoluble factions. SDS-PAGE (A) and Western-
blotting (B) were performed to examine the solubility of the E. coli-
expressed VP1 protein. Anti-GST tag monoclonal antibody was used
to recognize the VP1 protein. Lane M, pre-stained protein marker;
lane 1, soluble fraction; lane 2, insoluble fraction.
Lee et al. Microbial Cell Factories 2011, 10:56
http://www.microbialcellfactories.com/content/10/1/56
Page 6 of 11Figure 8 Purification of recombinant GST-opt-VP1 protein. (A) Chromatographic profile of GST-opt-VP1 protein eluted from a GSTrap FF
affinity column. The cytosolic extract of E. coli strain BL21(DE3)-pLysS expressing GST-opt-VP1 protein was loaded into the GSTrap FF column
and the bound protein was eluted with elution buffer as described in Material and Methods. (B) SDS-PAGE analysis of the eluted fractions
collected from the GSTrap FF affinity column. Lane M, pre-stained protein marker; lane 1, flow through; lane 2, fraction obtained after column
washing, lane 3 and 4, eluted fraction 1 and 2, respectively, collecting after column elution. (C) Identity of the GST-opt-VP1 protein determined
by MALDI-TOF. The bold letters represent actual amino acid matches.
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gous recombinant protein; these include cost-effectiveness,
time-saving, ease of production and the fact that the anti-
genic characterization of recombinant protein are easier to
confirm. Therefore, E. coli expression systems are the
most used approaches when screening for the expression
of a foreign protein [15]. Indeed, among above points are
many of the critical factors associated with choosing a sui-
table production system for the development of a subunit
vaccine and diagnostic kit. However, in previous studies,
there have many difficulties when expressing full-length
CAV VP1 protein using E. coli as the expression host
[9,11]. In addition to VP1 protein expression, proteolysis
in E. coli also seems to occur resulting in the degradation
of the VP1 protein [9]. Although an N-terminus deleted
VP1 has been successfully expressed in E. coli, neverthe-
less, the use of a truncated form of the CAV VP1 protein
m i g h th a m p e r si t su s e f u l n e s si ns e r o l o g i c a lt e s t so ra sa
subunit vaccine. Thus, the problems caused by the lack of
a truly effective system for producing VP1 protein still
needed to be overcome.
Using Genscript OptimumGene™ bioinformatic soft-
ware, the rare codons in E. coli that exist in the wild-
type CAV VP1 gene were analyzed. These amino acid
residues include arginine, leucine, proline and lysine,
which are common in the N-terminus region of the VP1
protein (1-321 bp). Rosenberg et al proposed that the
abundance of rare codon near the 5’-end of the gene
might affect the efficiency of protein translation and this
suggested the present approach to increasing expression
of the full-length CAV protein [16].
Both of porcine circovirus (PCV) and CAV are mem-
bers of the circovirus family. PCV also has similar basic
amino acid residues rich in rare codons at the N-termi-
nus of the capsid protein and this also results in
decreased protein expression [17]. However, Liu et al
successfully overcame this problem by fusing a maltose-
binding protein (MBP)-His × 8 tag to the PCV capsid
protein for expressing and the resulting fusion protein
in E. coli [ 1 8 ] .W h yt h ep r e s e n c eo faM B P - H i s×8t a g
improves protein expression remains unclear, but one
possibility is improved protein solubility [19]. Similarly,
in the present study, the addition of a GST tag to the
VP1 protein improved expression in E. coli significantly
compared to a His × 6 tag (Figure 2B). Thus it would
seem that some fusion tags are able to promote better
expression in E. coli than other tags, perhaps by aiding
the correct folding of their fused partner protein [19].
This report is the first to show that full-length recombi-
nant CAV VP1 protein can be expressed successfully in
E. coli by adding a GST tag.
Presently, it had been recognized that VP1 is a sole
structural protein. This protein is not only an immuno-
gen for used as vaccine candidate but also suitable
Figure 9 Antigenicity of the expressed recombinant GST-opt-VP1 protein using CAV-infected chicken serum and Western blot analysis
(A). Lane M, pre-stained protein marker; lane 1, 2 and 3, purified GST-opt-VP1 protein was respectively recognized by anti-GST mAb, anti-VP1
mAb E3 and CAV-infected positive chicken serum. Reactivity of the chicken serum with the recombinant GST-opt-VP1 protein was also evaluated
by indirect ELISA (B). Five groups of CAV-infected positive chicken sera and one group of negative sera samples were used in a GST-opt-VP1
based ELISA. Five sera samples are involved in each group. These sera had been all identified as negative or positive using a commercial ELISA
kit purchased from the IDEXX laboratory.
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Page 8 of 11applied as a coating antigen of ELISA for diagnostic
purpose [7,8,10]. However, there has no any prokaryotic
expression system which successful employed for pro-
duction of full-length VP1 of CAV. In addition, the full-
length VP1 of CAV involved all of the epitopes which
can elicit virus neutralizing antibodies of the host. For
this study, the full-length VP1 protein was soluble with
80% of total expressed protein, and retained the anti-
genic characteristics of the native VP1 (Figure 7 and
9B). Thus, it implied that the most important immuno-
domain, the VP1 of the CAV capsid, can highly yield
produced herein, and will be used conveniently for
developing recombinant vaccine in the other further
studies.
Although the full-length of recombinant CAV VP1
protein was able to be expressed in E. coli by fusing the
VP1 protein with a GST tag, the yield of GST-VP1
remained relatively low at (approximately 3.78 mg/ml
(Figure 4B). This may be a result of poor protein stabi-
lity, the toxicity of CAV VP1 protein or others factor
including perhaps rare codons within the VP1 gene
[9,11]. When the full-length VP1 protein was expressed
in BL21 (DE3), BL21 (DE3)-pLysS and BL21 (DE3)-
CodonPlus-RP, the highest level of the full-length VP1
protein occurred with in BL21 (DE3)-pLysS. This per-
haps indicates that stain BL21 (DE3)-pLysS might be
more tolerant of any cytotoxicity. BL21 (DE3)-Codon-
Plus-RP was able to reach an expression level of 1.71
mg/ml at 1 h post-induction, which is about 30% higher
than in BL21 (DE3) and BL21 (DE3)-pLysS under the
same conditions (Figure 4B, C and 4D). One reason for
the increase in full-length VP1 expression by BL21
(DE3)-CodonPlus-RP cells might be the presence of
extra copies of the tRNA
argU, proL genes. However, such
over-expression might exhaust endogenous energy sup-
plies, which is deleterious to the cells, especially when
they are induced with IPTG induction. In this context,
it was found that IPTG induction of over 2 h, when the
bacterial cells were grown at 37°C, failed to increase the
yield of VP1 further to any significant degree. Also note-
worthy is the fact that the growth profile of BL21 (DE3)-
CodonPlus-RP during the course of expression of GST-
VP1 was not changed (Figure 4A). This phenomenon
might cause by a balancing of the steady-state growth
condition of the strains with yield, which suggests that
the strain had reached its maximum possible growth
rate for expressing full-length CAB VP1 [20].
In such circumstances, it seems likely that optimiza-
tion of codon bias would be a useful strategy to improve
the expression of full-length CAV VP1 protein. By engi-
neering the foreign gene to use E. coli’s preferentially
used codons; this will improve translation efficiency
without the need to supply extra copies of the rare
tRNA genes [21-23]. When the rare codons within the
N-terminus of the VP1 gene were optimized, expression
of full-length optVP1 protein in BL21 (DE3)-pLysS sig-
nificantly increased (Figure 5B, 6B). The comparably
higher yield of optVP1 to wild type VP1 or any other
published expression system after the rare codons had
been optimized within the N-terminus of VP1 protein
and using BL21 (DE3)-pLysS, was approximately 4.6
fold greater than for wild type VP1 at 1 h post-induc-
tion. Notably, an increase in induction to greater than 2
hours was not further increased the accumulation of
optVP1 protein. The limit may be the protein burden
within the E. coli cells, which eventually leads to growth
arrest (Figure 6A, B). However, using a fed-batch based
cultivation system, this difficulty might be overcome and
allow even higher yields of full-length VP1 protein to be
obtained in the future.
Conclusions
The expression of recombinant full-length VP1 protein
of CAV using a prokaryotic system was established suc-
cessfully and the yield was greatly improved by making
various adjustments to the expression system. Optimiza-
tion of codon usage within N-terminal region of VP1
protein was a most convenient and cost-effective way of
increasing the expression of full-length CAV VP1 pro-
tein in E. coli. This paves the way for large-scale pro-
duction of the full-length VP1 protein using this
approach, which will allow the full-length VP1 to be
used for the development of a subunit vaccine or a diag-
nostic test.
Methods
Bacterial strain and cells inoculation
BL21 (DE3) was obtained from Invitrogen Life Technol-
o g i e s( C a r l s b a d ,C A ) .B L 21-CodonPlus(DE3)-RP and
BL21(DE3)-pLysS were purchased from Stratagene (La
Jolla, CA). Overnight cultures (10 ml LB medium in 50
ml flasks) were grown at 37°C for strain activation.
Then 0.5 ml of the overnight culture were inoculated
into 50 ml LB medium and grown at 37°C for around 3
h by which time the optical density of culture had reach
0 . 5o fO D 600 for cell transformation or protein
expression.
Plasmid construction
A 1350 bp of cDNA encoding the full-length CAV VP1
protein was cloned into pET28a (Novagen, Madison,
WI) earlier (Figure 1A, panel a) (Lee et al., 2009) [11].
Using a specifically designed primer set, forward primer
CAV VP1 F: 5’-GCGGAATTCATGGCAAGAC-
GAGCTCGCAGA-3’ and reverse primer CAV VP1-R:
5’-GGGCTCGAGTCAGGGCTGCGTCCCCCAGTA-3’,
respectively containing the EcoRIa n dXhoIs i t e s ,t h e
full-length VP1 gene was amplified using the plasmid
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plasmid pGEX-4T-1 (GE healthcare, Piscataway, NJ),
which was then designated to be pGEX-4T-1-VP1 (Fig-
ure 1A, panel b). This construct carries the VP1 gene
flanked by the N-terminal glutathione-S-transferase
(GST) tag and will express a GST-VP1 fusion protein.
To generate the plasmid harboring the codon optimized
nucleotide sequence, a codon optimized fragment
encoding the first 107 amino acid residues of the N-ter-
minus of the VP1 capsid protein was fused with the C-
terminus of the VP1 protein using the 5’ and 3’ ends of
above two DNA fragments and overlapping PCR [13].
The PCR used three different primer sets, Opt-F1 (5’-
CCCGAATTCATGGCTCGTCGTGCTCGTCGT-3’)
and Opt-R1 (5’-CGCTAGCAGGAACTCTTTCAGGTT-
3’), Opt-F2 (5’-AACCTGAAAGAGTTCCTGCTAGCG-
3’) and CAV VP1-R for the first amplification and then
CAV VP1 F and VP1-R for the second amplification.
The result was a fragment containing the entire cDNA,
Opt-VP1, which was then ligated into pGEX-4T-1 and
designated to be pGEX-4T-1-Opt-VP1 (Figure 1A, panel
c). The constructed recombinant plasmids were trans-
formed into One Shot
® Top10 (Invitrogen, CA) chemi-
cally competent E. coli for the maintenance of the
recombinant plasmids and protein expression. Transfor-
mants that contained a gene of the correct size by PCR
were then checked using restriction enzyme digestion
and DNA sequence analysis.
Codon optimization of cDNA of the N-terminus VP1
protein
The codons of the cDNA of the N-terminus of VP1 pro-
tein (321 bp) were optimized based on the codon prefer-
ence of E. coli using Genscript OptimumGene™
designing software. The codon-optimized cDNA of the
N-terminus of VP1 protein was synthesized by Genomics
Biosci & Tech Co. (Taipei, Taiwan) and then assembled
into the C-terminus of VP1 protein to give the entire
VP1 gene using the approach described above [13].
Expression of full-length VP1 protein after codon
optimized in recombinant E. coli
The host E. coli strains BL-21(DE3), BL21-CodonPlus
(DE3)-RP and BL21 (DE3)-pLysS have different recom-
binant constructions and these strains were used for
protein induction and expression. The recombinant
strains were grown in LB medium in the presence of
kanamycin (50 μg/ml), ampicillin (50 μg/ml) or chlor-
amphenicol (34 μg / m l )a sa p p r o p r i a t ea t3 7 ° C .W h e n
the culture had reached an optical density (OD600)o f
0.5, isopropyl-b-D-thiogalactopyronoside (IPTG) at dif-
ferent concentrations was added to induce protein
expression and then growth was continued for 4 h.
After IPTG induction, samples of the cells were
harvested using centrifugation for 10 min at 10,000 rpm.
To determine the protein expression, the cell pellets
were resuspended in 1xSDS-PAGE sample buffer and
boiled for 5 min. The resulting lysates were then Wes-
tern blotted after separation on a 12.5% SDS-PAGE.
The expression level and concentration of the recombi-
nant VP1 proteins were determined as described in a
previous study [11].
Purification of recombinant VP1 protein using GST affinity
chromatography
To purify the recombinant VP1 proteins, the cells were
spun down from 50 mL of culture supernatant and
resuspended in GST resin binding buffer (140 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4,
pH 7.3). They were sonicated on ice three times for 3
minutes with a 20% pulsed activity cycle (MISONIX
Sonicator
® 300). The lysate was then centrifuged for 10
min at 10,000 rpm to remove the cell debris. The result-
ing cell supernatant was injected into a GSTrap FF affi-
nity column (GE healthcare, Piscataway, NJ) with 1 mL
of GSTrap resin at a flow rate of 0.5 ml/min. The
packed column was washed with a 10-fold volume of
binding buffer, and then the bound proteins were eluted
with elution buffer (50 mM Tris-HCl, 10 mM reduced
glutathione, pH 8.0) at 1 ml/min. Each fraction con-
sisted of 1 ml of elutant. The fractions were monitored
at OD280 using the optical unit of a liquid chromatogra-
phy system (AKTAprime plus, GE Healthcare
BioScience AB, Uppsala, Sweden). A putative peak con-
taining the recombinant CAV viral protein was identi-
fied and the eluant collected for analysis. The total
protein concentration of each fraction was determined
using a Micro BCA kit (Pierce, Rockford, IL) using
bovine serum albumin as the reference protein. The
purity of the protein sample was analyzed using aliquots
of the fractions by 12.5% SDS-PAGE and Western-blot-
ting with appropriate antibodies.
Mass spectrometry
To confirm the identity of the recombinant GST-opt-
VP1 protein directly expressed in E. coli or purified by
GSTrap FF column, the proteins were separated by
12.5% SDS-PAGE. The relevant band was then cut out
from the 12.5% SDS-PAGE gel after Coomassie blue
staining and digested with trypsin. The resulting samples
were subjected to the MALDI-TOF-MS mass spectro-
metry (ESI-QUAD-TOF) to allow amino acid sequence
identification of the protein, as described in a previous
study [11].
ELISA assay
The antigenicity of E. coli expressed VP1 protein after
purification was evaluated by ELISA assay. Briefly, 2 μg
Lee et al. Microbial Cell Factories 2011, 10:56
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wells plate for 1 h at 37°C. After washing, CAV-infected
positive serum was added and reacted for one another
hour at 37°C. Subsequently, following washing, second-
ary antibodies were added and this was followed by
color development as described in a previous study [14].
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